Vistagen Therapeutics, Inc.VTGN

Vistagen Therapeutics, a clinical-stage biotech with no approved products, reported a net loss of $69.7 million for the year ended March 31, 2026, and ended the period with just $30.8 million in cash. The company burned $66.4 million in operating cash over the same period, meaning its current cash pile covers less than six months of operations at that rate. Research and development spending absorbed $55 million, underscoring the cost of advancing a pipeline that has yet to produce a commercial product.

The company focuses on intranasal pherine product candidates for central nervous system disorders, with fasedienol as its lead candidate. On June 30, 2026, Vistagen presented topline results from the PALISADE-4 phase 3 public speaking challenge trial. The press release accompanying the presentation emphasised financial discipline and pipeline value but included the standard caution that there is no guarantee any candidate will receive regulatory approval or be commercially successful.

Vistagen's 10-K, filed June 15, 2026, shows total assets of $48.6 million against liabilities of $13 million, leaving stockholders' equity of $35.5 million. The company reported diluted earnings per share of negative $1.83 on a weighted average share count of 38.1 million. No revenue was recorded, and the operating loss stood at $72.1 million. The filing also notes a registered trademark for VISTAGEN in the U.S. and mentions potential compliance obligations under the EU GDPR.

The SEC EDGAR filing index and company facts JSON provide the full financial history and insider transaction records. Three Form 4 filings dated July 2, 2026, indicate insider activity immediately after the PALISADE-4 data release, though the direction of those trades is not specified in the evidence. The company's market narrative rests on the success of its clinical pipeline, while the financial statements tell a story of sustained cash consumption.

What changed this week is the public release of PALISADE-4 data, a binary event that could either validate the pipeline or leave the company with a shorter runway and fewer options. The evidence does not include the actual trial results, only the fact that they were presented. That gap between event and outcome is the tension at the centre of the file. A future filing with detailed efficacy and safety data would deepen the picture, as would any disclosure of financing plans or partnership agreements.